Compare Stocks → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison TSE:INNYSE:MDPCVE:NDVANASDAQ:VIRNYSEAMERICAN:ZOM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINInMed PharmaceuticalsC$4.19C$3.35▼C$13.86C$33.73MN/A29,552 shs17,035 shsMDPMeredith$58.78$18.00▼$59.16$2.70B2.07552,848 shs3.36 million shsNDVAIndivaC$0.07+8.3%C$0.07C$0.02▼C$0.13C$12.69M1.1197,385 shs53,511 shsVIRVir Biotechnology$9.41-1.6%$9.66$7.61▼$27.48$1.27B0.471.04 million shs173,922 shsZOMZomedica$0.14-14.6%$0.00$0.12▼$0.25$132.98M0.995.34 million shs4.81 million shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINInMed Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MDPMeredith0.00%0.00%0.00%0.00%-13.29%NDVAIndiva0.00%0.00%+18.18%-27.78%+8.33%VIRVir Biotechnology+0.21%+4.14%+0.31%+2.91%-60.88%ZOMZomedica0.00%0.00%-7.20%-3.27%-35.03%The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINInMed PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMDPMeredithN/AN/AN/AN/AN/AN/AN/AN/ANDVAIndiva1.7042 of 5 stars3.50.01.70.00.62.50.0VIRVir Biotechnology2.5889 of 5 stars3.31.00.00.02.63.31.3ZOMZomedicaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINInMed PharmaceuticalsN/AN/AN/AN/AMDPMeredithN/AN/AN/AN/ANDVAIndiva3.00BuyC$0.15130.77% UpsideVIRVir Biotechnology2.57Moderate Buy$33.57256.76% UpsideZOMZomedicaN/AN/AN/AN/ACurrent Analyst RatingsLatest MDP, VIR, ZOM, IN, and NDVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2024VIRVir BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.005/3/2024VIRVir BiotechnologyNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/3/2024VIRVir BiotechnologyJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$10.00 ➝ $12.003/15/2024VIRVir BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$110.002/23/2024VIRVir BiotechnologyJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$9.00 ➝ $10.002/14/2024VIRVir BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$85.00 ➝ $110.00(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINInMed PharmaceuticalsC$574.68K0.00N/A10.40C$0.76 per share0.00MDPMeredith$2.98B0.00N/A5.68$14.27 per share0.00NDVAIndivaC$37.57M0.34C$0.01 per share5.20N/A∞VIRVir Biotechnology$86.18M14.69N/AN/A$11.82 per share0.80ZOMZomedica$25.19M5.28N/AN/A$0.24 per share0.57Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINInMed PharmaceuticalsN/A-C$1.51N/AN/AN/AN/AN/AN/AN/AMDPMeredith$306.60M$5.9010.01N/AN/A9.66%41.72%4.92%N/ANDVAIndiva-C$4.92M-C$0.05N/A∞N/A-13.09%-544.76%-3.49%5/14/2024 (Estimated)VIRVir Biotechnology-$615.06M-$4.01N/AN/AN/A-677.69%-32.58%-26.97%8/1/2024 (Estimated)ZOMZomedica-$34.53M-$0.04N/A∞N/A-137.10%-8.13%-7.68%N/ALatest MDP, VIR, ZOM, IN, and NDVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024ZOMZomedicaN/A-$0.01-$0.01-$0.01N/A$6.26 million5/2/2024Q1 2024VIRVir Biotechnology-$0.99-$0.48+$0.51-$0.48$11.71 million$56.38 million 4/1/2024Q4 2023ZOMZomedicaN/A-$0.01-$0.01N/A$7.00 million$7.34 million 2/22/2024Q4 2023VIRVir Biotechnology-$1.14-$0.86+$0.28-$0.86$11.18 million$16.80 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINInMed PharmaceuticalsN/AN/AN/AN/AN/AMDPMeredithN/AN/AN/AN/AN/ANDVAIndivaN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/AZOMZomedicaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINInMed Pharmaceuticals8.482.131.45MDPMeredith4.031.391.36NDVAIndiva5,899.220.720.52VIRVir BiotechnologyN/A12.909.05ZOMZomedicaN/A11.0610.49OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINInMed PharmaceuticalsN/AMDPMeredith78.23%NDVAIndiva0.06%VIRVir Biotechnology65.32%ZOMZomedica8.95%Insider OwnershipCompanyInsider OwnershipINInMed PharmaceuticalsN/AMDPMeredith9.79%NDVAIndiva36.29%VIRVir Biotechnology15.60%ZOMZomedica4.18%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableINInMed Pharmaceuticals128.05 millionN/ANot OptionableMDPMeredith5,33045.78 million41.30 millionOptionableNDVAIndiva147,000195.30 millionN/ANot OptionableVIRVir Biotechnology587134.50 million113.52 millionOptionableZOMZomedica144979.95 million938.99 millionNot OptionableMDP, VIR, ZOM, IN, and NDVA HeadlinesSourceHeadlineZomedica Announces First Quarter 2024 Financial Results: Revenue up 14% to $6.3 Million; 66% Gross Margin, and $91 Million in Liquidityaccesswire.com - May 9 at 4:15 PMZomedica earnings: here's what Wall Street expectsmarkets.businessinsider.com - May 9 at 3:37 AMZomedica to Present at the EF Hutton Annual Global Conference on May 15, 2024accesswire.com - May 8 at 6:30 AMZomedica Corp.: Zomedica Expands International Reach with CE Certification for VetGuardian Systemfinanznachrichten.de - May 6 at 7:40 AMZomedica Expands International Reach with CE Certification for VetGuardian(R) Systemaccesswire.com - May 6 at 6:30 AMZomedica Strengthens Market Position with New Patents Issued for its TRUFORMA(R) Diagnostic Platformaccesswire.com - May 2 at 6:30 AMZomedica to Report First Quarter 2024 Financial Results and Provide Business Update on May 9th at 4:30 p.m. ETaccesswire.com - April 30 at 6:30 AMWhat’s Happening at the Defender Kentucky Three Day Eventeventingnation.com - April 21 at 12:53 PMZomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024accesswire.com - April 9 at 6:30 AMZomedica Corp. (AMEX:ZOM) Q4 2023 Earnings Call Transcriptmsn.com - April 2 at 4:06 PMQ4 2023 Zomedica Corp Earnings Callfinance.yahoo.com - April 2 at 8:30 AMZOM Stock Earnings: Zomedica Beats Revenue for Q4 2023investorplace.com - April 1 at 9:06 PMZomedica reports Q4 resultsmsn.com - April 1 at 5:27 PMZomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidityaccesswire.com - April 1 at 4:05 PMThe Next Millionaire-Makers: 3 Penny Stocks With Massive Upside Potentialinvestorplace.com - April 1 at 3:12 PMZomedica to Report Fourth Quarter and Full Year 20…pharmiweb.com - March 20 at 9:17 AMZomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ETaccesswire.com - March 20 at 6:30 AMZomedica Pharmaceuticals Corp (ZOM)investing.com - March 15 at 7:52 AMZomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platformaccesswire.com - March 14 at 6:30 AMZomedica Provides NYSE American Listing Updateaccesswire.com - March 13 at 4:45 PMSidoti & Company, LLC: Sidoti Events, LLC's Virtual March Small-Cap Conferencefinanznachrichten.de - March 12 at 11:26 AMZomedica Corp.: Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferencesfinanznachrichten.de - March 12 at 8:22 AMZomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferencesaccesswire.com - March 12 at 6:30 AMZomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogsaccesswire.com - March 7 at 6:30 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Seagate Technology Warns Cloud Demand is Heating Up April 30, 2024 10:10 AMView Seagate Technology Warns Cloud Demand is Heating Up Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesApril 25, 2024 10:36 AMView Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesBoston Scientific Bucks the Medtech Slow Down and Raises OutlookApril 30, 2024 10:34 AMView Boston Scientific Bucks the Medtech Slow Down and Raises OutlookAll Headlines Company DescriptionsInMed PharmaceuticalsTSE:INInMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.MeredithNYSE:MDPMeredith Corp. engages in television broadcasting and magazine advertising business. It operates through the Local Media and National Media business segments. The Local Media segment includes television stations and offers websites, mobile-optimized websites, and mobile applications. The National Media segment consists of national consumer media brands delivered via multiple media platforms including print magazines and digital and mobile media, brand licensing activities, database-related activities, and business-to-business marketing products and services. The company was founded by Edwin Thomas Meredith in 1902 and is headquartered in Des Moines, IA.IndivaCVE:NDVAIndiva Limited engages in the production, processing, and sale of cannabis and cannabis related products in Canada. It offers pre-rolls, flower, capsules, and edible and extract products under the INDIVA, Indiva Life, and Artisan Batch brands. The company produces and distributes the Bhang Chocolate, Wana Sour Gummies, Jewels Chewable Tarts, Grön edibles, and Dime Industries vape products through license agreements and partnerships. Indiva Limited is based in Ottawa, Canada.Vir BiotechnologyNASDAQ:VIRVir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.ZomedicaNYSEAMERICAN:ZOMZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.